SAN2355

SAN2355

Jan 3, 2024

OUR PIPELINE SAN2355 – A selective Kv7.2/Kv7.3 activator SAN2355 – A selective Kv7.2/Kv7.3 activator Unprecedented subtype selectivity for treatment of epilepsy SAN2355 is the first clinical candidate from the Kv7 epilepsy program. SAN2355 is a subtype-selective...

test child pages

Dec 18, 2023

Saniona’s labs in DenmarkOur Pipeline Proprietary Pipeline What does it take to develop a drug? What is a clinical trial? What are the phases of clinical development? And how is this process sometimes different for rare diseases? Learn...
SAN2355

Epilepsy

Dec 13, 2023

PATIENTS & CAREGIVERS Epilepsy What is epilepsy? Epilepsy is one of the most common and disabling chronic neurological disorders and currently affects more than 50 million people worldwide, including 3.4 million in the US and 3.2 million people in the EU. There is...